ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / RIGL
ORIC (30) SVRA (34) LTGO (41) MLTX (32) ⌘ Pro Terminal →

Rigel Pharmaceuticals Inc. (RIGL) — RQD Stock Rating Cockpit

$50.53 -1.52% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $50.51

Rigel Pharmaceuticals Inc. (RIGL) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (93.3% gross margin, 28% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $958.5M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on RIGL Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is RIGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $50.53 (-1.52% 1D, market cap $958.5M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, RIGL ranks #32 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does RIGL compare to ORIC and SVRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RIGL carries a Roarable B (75/100 RQD), trailing P/E of N/A, gross margin of 93.3%, and ROIC of 28.2%. By comparison, ORIC (Oric Pharmaceuticals Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -33.4%, cap $957.8M) and SVRA (Savara Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $990.3M). Among the 5-stock peer group, RIGL leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for RIGL?
▼

Per RIGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001034842), Rigel Pharmaceuticals Inc. generated $294.3M in revenue (+64.1% YoY), $367.0M in net income, and $75.7M in free cash flow against $513.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $50.51 (-0.03%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 13/20 (C) • 25.7% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 75/100 (B) historically ranked in the Top 12% of excess returns over the next 90 days (+7.4% avg 90D alpha vs SPY • 69.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510075
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B
Cash (13)Whales (16)SEC (14)Macro (15)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+7.7% Base Target
$64 Bull$54 Base$41 Bear
📬 FREE RIGL RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for RIGL)Realized 20D OHLCV Swing Band: ±7%
Deterministic 5-Pillar Attribution (75/100 Composite)
🔍 WHY RIGL SCORES 75/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Whale & Options Positioning+16/20 pts (21% of score)

20D Institutional Volume Accumulation (±7% realized swing band)

▼ #1 Drag / Risk Factor: Cash Engine Quality13/20 pts (-7 pt drag)

Capital intensity & 42.6% operating margin leave 7 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
67
Grade B-$47.14+2.1% Next Q
Q2 (-2Q)
70
Grade B$48.11+5.1% Next Q
Q3 (-1Q)
72
Grade B$50.55+0% Next Q
Current
75
Grade B$50.53+7.4% Hist 90D α
Trajectory: B- (67) → B (75)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the RIGL Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 75/100 (B) score, RIGL faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 90.8% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($47.93) or 200D SMA ($37.28) invalidates the momentum regime and cuts Target Base ($54.40) toward Bear Floor ($41.43).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $RIGL• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “RIGL Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 75%NO 25%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
63.930 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.64>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE92% OF RANGE
L: $25$50.53H: $53
1. Money & Cash Health● MIXED
Are profits real cash in the bank?

Decent core business (93.3% gross margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: A-RQD 33 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: BRQD 29 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bullish on RIGL

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
NEUTRAL (65)

28.2% ROIC with 93.3% gross margin and 7.87% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (70)

Altman-Z 3.64 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (80)

33/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like RIGL
  • ✓Big institutional funds and options desks are actively positioning on the bullish side.
  • ✓Company leadership has skin in the game with net positive insider conviction.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (RIGL Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
RIGL // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +71.06%⚡ TESTING RESISTANCE
2026-11-03O $51.45H $51.45L $50.53C $50.53VOL 174.4K
RES: $52.75SUP: $48.32SMA50: $47.93SMA200: $37.28
$54.51$46.63$38.76$30.88$23.01RES $52.75SUP $48.32$50.532026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

RIGL Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 RIGL Butterfly Map → + Track RIGL →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
-3.0%/yr Implied 5Y Growth

vs. +64.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on RIGL today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for RIGL. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for RIGL today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (RIGL)

Health Care Rank #32 of 1015 ⚔️ ORIC vs RIGL Full Matrix →

1. Head-to-Head Health Care Peer Comparison (RIGL vs. ORIC, SVRA, LTGO, MLTX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Rigel Pharmaceuticals Inc. (RIGL) ranks #32 by composite RQD confidence (75/100, grade B) and #360 by equity capitalization ($958.5M). Within this direct 5-issuer industry benchmark cohort, RIGL leads on earnings valuation at N/A trailing P/E, while RIGL leads on capital efficiency and profitability with 28.2% ROIC and 93.3% gross margin. RIGL currently leads its immediate peer cohort in composite quantitative strength at 75/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
RIGL ACTIVE
Rigel Pharmaceuticals Inc.
B 75/100 — 93.3% 28.2% -1.52% $958.5M Benchmark Subject
ORIC
Oric Pharmaceuticals Inc.
E 30/100 — — -33.4% -1.84% $957.8M /oric-vs-rigl →
SVRA
Savara Inc.
E 34/100 — — -35.0% -1.87% $990.3M /svra-vs-rigl →
LTGO
Latigo Biotherapeutics Inc.
D- 41/100 — — — -3.15% $924.9M /ltgo-vs-rigl →
MLTX
MoonLake Immunotherapeutics (Class A)
E 32/100 — — -35.0% -2.63% $1.00B /mltx-vs-rigl →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001034842 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Rigel Pharmaceuticals Inc. (RIGL) reported GAAP revenue of $294.3M (+64.1% vs. FY2024 revenue of $179.3M , and +151.8% cumulative change since FY2023) , GAAP net income of $367.0M, operating cash flow of $75.7M, and free cash flow of $75.7M (+140.4% YoY). On the balance sheet, RIGL closed FY2025 with $513.6M in total assets against $0 in total debt (Altman Z-Score: 3.64, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $294.3M $367.0M $75.7M $75.7M $513.6M —
FY2024 (FY) 2024-12-31 $179.3M $17.5M $31.5M $31.5M $164.0M —
FY2023 (FY) 2023-12-31 $116.9M -$25.1M -$5.7M -$5.7M — —

3. RIGL Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is RIGL stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $50.53 (-1.52% 1D, market cap $958.5M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 16/20, SEC Balance-Sheet Forensics 14/20, FRED Macro Regime Fit 15/20, and Executive Insider Alignment 17/20. Across 1015 tracked Health Care issuers, RIGL ranks #32 in composite RQD confidence.

How does RIGL compare to ORIC and SVRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RIGL carries a Roarable B (75/100 RQD), trailing P/E of N/A, gross margin of 93.3%, and ROIC of 28.2%. By comparison, ORIC (Oric Pharmaceuticals Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -33.4%, cap $957.8M) and SVRA (Savara Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $990.3M). Among the 5-stock peer group, RIGL leads on earnings multiple (N/A) while RIGL leads on capital efficiency (28.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for RIGL?

Per RIGL's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001034842), Rigel Pharmaceuticals Inc. generated $294.3M in revenue (+64.1% YoY), $367.0M in net income, and $75.7M in free cash flow against $513.6M in total assets and $0 in total debt. Key quantitative strengths: Big institutional funds and options desks are actively positioning on the bullish side. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is RIGL trading relative to its 50-day, 200-day, and 52-week technical levels?

RIGL last traded at $50.53 (-1.52% on volume of 136,088 shares), positioning the stock +5.42% above its 50-day simple moving average ($47.93) and +35.54% above its 200-day simple moving average ($37.28). Across its 52-week range of $24.95 to $52.61, RIGL sits at the 92.5% percentile with a 14-day RSI of 63.9 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.0% ($46.99 to $54.07).

Direct Sub-Reports: RIGL RQD Cockpit RIGL 12M Forecast RIGL Earnings & Move RIGL Dividends & DRIP RIGL Insiders & 13F RIGL Whale Options RIGL Profit Sankey RIGL News & Why
ROARABLE RATING BRIEF • RQD 75/100 (B) ✓ SEC XBRL & RQD VERIFIED

RIGL — Rigel Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Rigel Pharmaceuticals Inc. (RIGL) earns a live Roarable RQD composite score of 75/100, corresponding to a B letter grade (Roarable Buy) at a spot price of $50.53 (-1.52% 1D, market capitalization $958.5M).

  • Fundamental Cash Engine (13/20): Anchored by return on invested capital (ROIC) of 28.2%, gross margin of 93.3%, operating margin of 42.6%, and free cash flow yield of 7.87%.
  • Whale 13F & Options Flow (16/20) + Insider Conviction (17/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (15/20) + Forensic Balance Sheet (14/20): Incorporates a 1.00x equity beta, Altman Z-Score of 3.64, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Rigel Pharmaceuticals Inc. (RIGL) is a NASDAQ-listed company in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry..0B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Rigel Pharmaceuticals Inc. (RIGL) reported $294.3M in annual revenue (up from $179.3M in FY2024, +64.1% YoY) and $367.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($116.9M revenue, -$25.1M net income) through FY2025, RIGL scaled operating cash flow to $75.7M and free cash flow to $75.7M, backed by $513.6M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B • RQD 75/100): Big institutional funds and options desks are actively positioning on the bullish side. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 13/20 and Institutional Whale Flow at 16/20, sustained execution supports upside toward the upper end of the $24.95 – $52.61 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh current valuation and 7.3x EV/EBITDA against 42.6% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), RIGL carries a macro regime beta of 1.00 and gross margin of 93.3%.

  • Key Question #1: Can RIGL sustain or expand its 42.6% operating margin and 28.2% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $294.3M and free cash flow of $75.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is RIGL's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

RIGL Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Rigel Pharmaceuticals Inc. (RIGL) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to RIGL Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

RIGL Bull vs. Bear Conversation Board — What's Your Call at $50.53?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON RIGL 🐻 33% BEARISH CONVICTION
1. Pick Your Side on RIGL:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH 🎯 Target: $65.16 (+27.0%)
📌 Pinned Debate

Per the RQD rating, insider conviction (17/20) and a 28.2% ROIC with a 7.87% FCF yield point to a strong cash engine backed by buying a

Per the RQD rating, insider conviction (17/20) and a 28.2% ROIC with a 7.87% FCF yield point to a strong cash engine backed by buying activity.. When you look under the hood at RIGL, Fundamental Cash Engine is 13/20 with 93.3% gross margins and 28.2% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (16/20) has been quietly accumulating below $52.61. My 12M target is $65.16.

SectorRotator 🐂 BULL

@DeepValue_CFA Agree on the RQD 75/100 quality, though with 1.0 beta I'm scaling in with half-size at $51.31 and keeping dry powder in case we test $47.72.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $41.05 (-20.0%)
Spot @ $51.31

Valuation & margin reality check on RIGL at $51.31 before chasing here

Careful chasing RIGL at $51.31. Valuation & margin reality check on RIGL at $51.31 before chasing here. Gross margin is 93.3%, but operating margin is 42.6%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $41.05 on multiple compression.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%